N@N

SYDNEY--([ BUSINESS WIRE ])--Sirtex Medical Limited (ASX:SRX) has reported revenue growth of 18 per cent to$83 million with record dose sales of 6,141 worldwide, up 23 per cent for the period ended 30 June 2012.

"Guided by our 2020Vision strategy, Sirtex is creating a scalable global infrastructure to meet significant future demand for our targeted radiation therapy in established and new markets worldwide"

Profit before income tax was up 54 per cent to $22 million. Net profit after tax was up 49 per cent to $17 million. EPS is 30.7 cents and net tangible assets per share were 102.8 cents.

Sirtex Medical Limited Chief Executive Officer, Mr Gilman Wong said, aOur business has performed very well with dose sales improving in all regions. We continue to invest in and build our business with a focus on creating sustainable long-term growth through our ability to serve a growing global customer base providing clinically effective oncology solutions that help improve outcomes for patients with liver cancer.

aGuided by our 2020Vision strategy, Sirtex is creating a scalable global infrastructure to meet significant future demand for our targeted radiation therapy in established and new markets worldwidea. Mr Wong said.

Regional performance

In the US, the investment in sales and marketing support staff combined with a renewed focus to educate the referral and oncology communities delivered exceptional results. US dose sales grew 32 per cent to deliver $57 million revenue. The business in Europe achieved dose sales growth of four per cent and $22 million in revenue. We continued to invest in European support staff and prepare for growth ahead. The Asia Pacific region grew dose sales 37 per cent to reach $4 million in revenue. Sirtex expects strong growth trends in all markets to continue in 2013.

Foundations for future growth

Sirtex continues to make the necessary investments in clinical studies, sales and marketing, manufacturing, and R&D to create the foundations for future expansion. During the year, the company invested $8.5 million to support five major post-marketing clinical studies and we are expediting the development of new delivery technology for SIR-Spheres microspheres.

These programs aim to make the SIR-Spheres microspheres easier to administer and move it from a last line treatment to a preferred first line standard offered to a larger patient population. All clinical studies are recruiting well with the SIRFLOX clinical study due to complete recruitment within six months.

Higher manufacturing volumes reflected a minor increase in gross margin to 81 per cent compared to 80.8 per cent last year. As at 30 June 2012, Sirtex has no debt and a cash balance of $49 million.

SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd.